Immuneering earnings were -$62.1M for the trailing 12 months ending Jun 30, 2025, with N/A growth year over year. The latest IMRX earnings report on Jun 30, 2025 announced Q2 2025 earnings of -$14.4M, down 4.1% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, IMRX reported annual earnings of -$61.0M, with 14.1% growth. The next IMRX earnings date is Nov 6, 2025.
On IMRX's earnings call on Invalid Date, Immuneering (NASDAQ: IMRX) reported Q2 2025 earnings per share (EPS) of -$0.40, up 14.89% year over year. Total IMRX earnings for the quarter were -$14.43 million. In the same quarter last year, Immuneering's earnings per share (EPS) was -$0.47.
The next IMRX earnings date is Invalid Date. Add IMRX to your watchlist to be reminded of Immuneering's next earnings date.
Is Immuneering profitable or losing money?
As of the last Immuneering earnings report, Immuneering is currently losing money. Immuneering's net profit (also called net income) for the twelve months ending Jun 30, 2025 was -$62.13 million, a 10.81% increase year over year.
What was IMRX's earnings growth in the past year?
As of Immuneering's earnings date in Invalid Date, Immuneering's earnings has grown year over year. IMRX earnings in the past year totalled -$62.13 million.
What are Immuneering's earnings expectations?
The current EPS estimate for Immuneering's earnings report in Invalid Date is -$0.38.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.